AR056814A1 - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
AR056814A1
AR056814A1 ARP060105038A ARP060105038A AR056814A1 AR 056814 A1 AR056814 A1 AR 056814A1 AR P060105038 A ARP060105038 A AR P060105038A AR P060105038 A ARP060105038 A AR P060105038A AR 056814 A1 AR056814 A1 AR 056814A1
Authority
AR
Argentina
Prior art keywords
disorders
pharmaceutical composition
pharmaceutical compositions
thiazepine
dibenzo
Prior art date
Application number
ARP060105038A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR056814A1 publication Critical patent/AR056814A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion provee métodos de tratamiento con una composicion farmacéutica, más particularmente una composicion farmacéutica de liberacion sostenida, que comprende 11-[4-[2-(2-hidroxietoxi)etil]-1-piperazinil]dibenzo-[b,f][1,4]tiazepina o una sal farmacéuticamente aceptable de la misma, así como también nuevos y mejorados métodos para tratar una variedad de trastornos y afecciones psicologicos que incluyen, pero que no se limitan a, Trastornos del Estado de ánimo y Trastornos de Ansiedad y para tratar uno o más de los síntomas de estos trastornos.
ARP060105038A 2005-11-18 2006-11-16 Composiciones farmacéuticas AR056814A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73794305P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
AR056814A1 true AR056814A1 (es) 2007-10-24

Family

ID=38048902

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105038A AR056814A1 (es) 2005-11-18 2006-11-16 Composiciones farmacéuticas

Country Status (8)

Country Link
US (2) US20070185080A1 (es)
EP (1) EP1951256A1 (es)
JP (1) JP2009515952A (es)
CN (1) CN101360504A (es)
AR (1) AR056814A1 (es)
TW (1) TW200735878A (es)
UY (1) UY29924A1 (es)
WO (1) WO2007058593A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976487A2 (en) * 2006-01-25 2008-10-08 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
EP2236511A4 (en) 2007-12-21 2011-04-13 Alla Chem Llc LIGANDS OF ALPHA ADRENOCEPTORS AND OF DOPAMINE, HISTAMIN, IMIDAZOLIN AND SEROTONIN RECEPTORS AND THEIR APPLICATION THEREOF
US20110052648A1 (en) * 2008-03-12 2011-03-03 Avi Avramoff Oral modified-release formulations containing thiazepines
BRPI0912161A2 (pt) * 2008-05-30 2015-10-06 Ucb Pharma Sa composição farmacêutica na forma de um tablete
CN101912374B (zh) * 2010-08-08 2016-01-20 浙江华海药业股份有限公司 喹硫平缓释片及其制备方法
US20120258994A1 (en) * 2010-12-03 2012-10-11 Mckinney Anthony Alexander Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters
CN102525988B (zh) * 2011-01-04 2016-01-06 北京天衡药物研究院 富马酸喹硫平缓释片
CN102218042A (zh) * 2011-05-26 2011-10-19 青岛黄海制药有限责任公司 富马酸喹硫平组合物的缓释片剂及其制备方法
CN104586805A (zh) * 2014-07-08 2015-05-06 上海中西三维药业有限公司 富马酸喹硫平缓释片剂及其制备方法
EP3618698A4 (en) 2017-05-05 2021-01-06 Canary Speech, LLC VOICE-BASED MEDICAL ASSESSMENT
AU2019397565A1 (en) * 2018-12-14 2021-07-08 Praxis Precision Medicines, Inc. Methods for the treatment of depression
JP2022553943A (ja) * 2019-10-17 2022-12-27 ハーキュリーズ エルエルシー 分散可能な徐放性組成物およびその調製方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
EP1551393A4 (en) * 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic

Also Published As

Publication number Publication date
WO2007058593A1 (en) 2007-05-24
US20110319384A1 (en) 2011-12-29
JP2009515952A (ja) 2009-04-16
TW200735878A (en) 2007-10-01
US20070185080A1 (en) 2007-08-09
EP1951256A1 (en) 2008-08-06
CN101360504A (zh) 2009-02-04
UY29924A1 (es) 2007-06-29

Similar Documents

Publication Publication Date Title
AR056814A1 (es) Composiciones farmacéuticas
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
ECSP088499A (es) Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
BRPI0412909A (pt) uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
SV2008002511A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
PA8493701A1 (es) Compuestos para tratar la obesidad
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
ES2674129T3 (es) Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
UY30098A1 (es) Compuestos de tiazol y metodos de uso
SV2010003497A (es) Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis
UY32391A (es) Compuestos amino-heterocíclicos
ECSP055867A (es) Derivados de pirrolopirimidina
UY29320A1 (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, así como preparaciones farmacéuticas que las contienen
CO6460766A2 (es) Compuestos de haloalquil heteroaril benzamida
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
NI200800253A (es) Tetrahidro-pirimidoazepinas como moduladores de trpv1
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
FR2901467B1 (fr) Prothese anatomique pour le traitement des hernies, telles que hernies inguinales et crurales et autres
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
AR056846A1 (es) USO DE UN ANTAGONISTA DE CB1 PARA TRATAR EFECTOS SECUNDARIOS Y SíNTOMAS NEGATIVOS DE LA ESQUIZOFRENIA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal